Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Simpson, G. M. Articles by Romano, S. J. Search for Related Content PubMed Citation Articles by Simpson, G. M. Articles by Romano, S. J. Atypical Neuroleptics Schizophrenia Spectrum Disorders

Six-Month, Blinded, Multicenter Continuation Study of Ziprasidone Versus Olanzapine in Schizophrenia

OBJECTIVE: The authors’ goal was to compare the efficacy and tolerability of 6 months’ treatment with flexible-dose ziprasidone and olanzapine in patients with schizophrenia or schizoaffective disorder. METHOD: Brief Psychiatric Rating Scale (BPRS) scores and Clinical Global Impression (CGI) severity scores were obtained for 126 responders to a 6-week acute study of olanzapine and ziprasidone during a blinded 6-month continuation study and optional extension study. RESULTS: Comparable improvements in BPRS and CGI severity scores were seen with both drugs. Olanzapine produced significant increases from acute-study baseline values in weight and body mass index and within-group increases in total cholesterol, low-density lipoprotein cholesterol, and fasting insulin. Between-group differences were not significant for lipids and insulin. Mean QTc values at endpoint were 407.1 msec (baseline mean=406.0 msec) and 394.4 msec (baseline mean=399.7 msec) for ziprasidone and olanzapine, respectively. No patient had a QTc interval 500 msec. CONCLUSIONS: Ziprasidone and olanzapine had comparable long-term efficacy; olanzapine was associated with significant weight gain and metabolic alterations.

This article has been cited by other articles:

				P. F. Buckley, A. Foster, and B. Miller Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics Focus, January 1, 2008; 6(2): 172 - 179. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us